AUSTIN, Texas--(BUSINESS WIRE)--Oct 12, 2025--

Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that 14 studies featuring its technology will be presented at the European Society for Medical Oncology (ESMO) Congress, taking place October 17–21 in Berlin, Germany. The slate includes six oral presentations, reinforcing Natera’s position as a leader in molecular residual disease (MRD) testing across multiple cancer types.

Bladder Cancer Highlights

The IMvigor011 trial , sponsored by Genentech, a member of the Roche Group, has been selected for a Presidential Symposium on October 20. With positive topline results announced in August, this oral presentation will include additional data on Signatera’s ability to predict disease-free su

See Full Page